Oral region
J&J Reports Positive Phase 3 MajesTEC-9 Results for Tecvayli in Earlier Multiple Myeloma
Tecvayli; J&J; Phase 3; MajesTEC-9; multiple myeloma; PFS; OS
OS Therapies Seeks Expedited FDA Approval Following Successful Mid-Stage Osteosarcoma Trial
OS Therapies, FDA approval, osteosarcoma, OST-HER2, mid-stage trial, expedited approval
HLTH24: Atropos Health Introduces AI-Powered Chat Co-Pilot for Rapid Real-World Evidence Generation
Atropos Health, HLTH24, Chat-Based AI Co-Pilot, Real-World Evidence, Generative AI, Healthcare Evidence Generation, GENEVA OS, ChatRWD
OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange